Lv41
680 积分 2021-01-25 加入
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
6小时前
已关闭
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
4天前
已完结
Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI
7天前
已完结
Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?
7天前
已完结
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
9天前
已完结
Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy
24天前
已完结
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
1个月前
已完结
Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
1个月前
已完结
Case Report: CAR‐T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation
1个月前
已完结
Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia
1个月前
已完结
皖公网安备34019202002308
